J22352 is a highly selective HDAC6 inhibitor with proteolysis-targeting chimera (PROTAC)-like properties, used to promote HDAC6 degradation and exert anticancer effects by inhibiting glioblastoma autophagy and inducing antitumor immune responses; it also restores host antitumor immunity by reducing the immunosuppressive activity of PD-L1.